Search Results
Dec 03, 2025, 14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
distribution, and neuroinflammatory pathways.Recent highlights:GLP studies underway with positive PK, biodistribution, and CNS-penetration modelingRegulatory-facing package expected to mature in 2026.GDNF-Based Weight-Loss & Metabolic Program (VA
More news about: Hoth Therapeutics, Inc.
Dec 03, 2025, 09:00 ET Benuvia Operations Announces Strategic Partnership with Cannovation Clinical Research Partners to Deliver Fully Integrated Solutions for Controlled-Substance Therapeutics
emerging CNS therapeuticsComprehensive commercialization support to accelerate the safe, compliant delivery of new medicines to patientsAccelerating Innovation in Psychedelics, Cannabinoids, and Novel TherapeuticsAs research into psychedelic and cannabinoid-based CNS treatments
More news about: Benuvia Operations, LLC
Dec 02, 2025, 09:00 ET Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
business development, commercial strategy, and R&D leadership in advancing first- or best-in-class therapies for cardiometabolic, rare/genetic, and CNS diseases. He founded the precision cardiology therapeutic area at BioMarin, serving as Head of Cardiovascular R&D, where he built an extensive portfolio
More news about: Thryv Therapeutics Inc.
Dec 02, 2025, 07:00 ET Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
differentiation. Th1/Th17 cells play a central role in central nervous system (CNS) inflammatory diseases such as multiple sclerosis (MS). Inhibiting TYK2 reduces the activation of pro-inflammatory T cells, thus lowering CNS inflammation. LNK01006 demonstrated high brain penetration in preclinical species
More news about: Lynk Pharmaceuticals Co., Ltd.
Dec 02, 2025, 06:59 ET Garmin G5000H selected for Brazilian Air Force UH-60 Black Hawk helicopters
Marketing, Programs & SupportThe G5000H provides operators with the latest communication, navigation, surveillance air traffic management (CNS/ATM) capabilities with COTS solutions based on Garmin's modern open system architecture design. Mission management systems can be integrated along with
More news about: Garmin International, Inc.
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
PRECAUTIONSSomnolenceDIACOMIT can cause somnolence. Monitor patients for somnolence, particularly when DIACOMIT is used concomitantly with other CNS depressants or clobazam, which is also known to cause somnolence.Decreased Appetite and Decreased WeightDIACOMIT can cause decreases
More news about: Biocodex, Inc.
Nov 28, 2025, 05:46 ET CRO Industry to Hit USD 127.77 Billion by 2030 Driven by Advanced Clinical Trial Models and Led by North America, Says Mordor Intelligence
ServicesConsulting ServicesBy Therapeutic Area OncologyInfectious DiseasesCentral Nervous System (CNS) DisordersImmunological DisordersCardiovascular DiseasesRespiratory DisordersDiabetesOther Therapeutic AreasBy
More news about: Mordor Intelligence Private Limited
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
beta-thalassemia, and bone marrow failure syndromes are seeing breakthrough approvals in gene therapy and biologics.Central Nervous System (CNS)CNS held 12% (USD 26.8 billion). Rare neuromuscular disorders, inherited neurological conditions, mitochondrial diseases, and epilepsy subtypes
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 04:04 ET Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
lives of people with CNS disorders through continuous innovation and strong partnerships. With this launch, we are taking another important step in our journey to improve the daily lives of people with epilepsy. This breakthrough embodies our commitment to digital personalised CNS care, helping patients
More news about: Neuraxpharm
Nov 26, 2025, 21:39 ET SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights
More news about: SK Biopharmaceuticals. Co., Ltd.
Nov 26, 2025, 17:26 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:25 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:23 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:15 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:09 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
ZYMFENTRA.NEUROLOGIC REACTIONSAgents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders,
More news about: Celltrion
Nov 25, 2025, 05:01 ET Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% | Research by Vantage Market Research
complex generics requiring advanced delivery systems.By Therapeutic ApplicationCentral Nervous System (CNS): CNS generics maintain strong demand due to high prevalence of epilepsy, depression, anxiety, and neurodegenerative conditions. Patent expires in psychiatric
More news about: Vantage Market Research
Nov 24, 2025, 10:01 ET Regenerative Medicine Market to Skyrocket to USD 403.86 Billion by 2032 Driven by Cell & Gene Therapy Breakthroughs, Stem Cell Advancements, and Multi-Indication Expansion
TherapyStem cell therapy accounted for 17% (USD 8.2 billion), driven by allogeneic and autologous products for musculoskeletal, dermatology, CNS, and cardiovascular applications. MSC-based therapies continue to dominate due to their strong safety profile and multi-organ repair potential.By
More news about: DataM Intelligence 4 Market Research LLP
Nov 24, 2025, 10:00 ET GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy
proprietary central nervous system (CNS) platform technology, developed by Dr. Wilson's research team and licensed from the University of Pennsylvania, showed a reassuring preclinical safety profile and durable expression in NHP studies. Notably, in research animals, the direct CNS delivery via ICM injection
More news about: GEMMA Biotherapeutics
Nov 24, 2025, 05:19 ET Drs. Elliott Brea, Esther Redin, and Gavitt Woodard Announced as Recipients of LUNGevity's Career Development Awards
treatment directly into the CNS tumor site, to reduce contact with healthy tissue expressing TROP-2. The second method is to genetically modify the CAR-T cells to limit their ability to enter healthy epithelial tissue. If successful, this research will revolutionize the way we treat CNS in patients with EGFR-positive
More news about: LUNGevity Foundation
Nov 21, 2025, 13:30 ET Researchers Highlight Genetic Factors in Pediatric Brain and Spinal Cord Tumors
nervous system (CNS) are the leading cause of cancer-related deaths in children, with more than 47,000 children and young adults diagnosed each year. While up to one in four children with cancer carry rare genetic variants that increase cancer risk, the specific genetic drivers of pediatric CNS tumors remain
More news about: Children's Hospital of Philadelphia
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present new data on cenobamate, an anti-seizure medication, at the 2025 American
More news about: SK Life Science, Inc.
Nov 21, 2025, 03:01 ET HRV Pharma and MetroChem Forge Strategic CDMO Alliance to Fast-Track High-Value NCE-1 API Development
marketsGlobal regulatory DMF filings (US, EU, LATAM, MENA & APAC) with shared technical dossiersA long-term, pipeline-led framework covering novel CNS, metabolic and specialty therapeutic APIsA unified quality, compliance and audit readiness program designed for USFDA, EMA, PMDA, ANVISA and
More news about: HRV Pharma
Nov 20, 2025, 15:00 ET Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and multiple other disease indications including where ROCK2 plays a pivotal role in pathology. Graviton's first drug candidate,
More news about: Graviton Bioscience
Nov 20, 2025, 08:30 ET Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive
More news about: Neurocrine Biosciences, Inc.